Аңдатпа
Akkermansia muciniphila is increasingly linked to host metabolic, immune, and neurobehavioral phenotypes, yet taxon-level associations are often inconsistent across studies and disease contexts. This review advances an effector-centered framework to explain how A. muciniphila acts through host-facing molecules, including outer membrane and secreted proteins such as Amuc_1100 (pilus-associated signaling, PAS) and P9, extracellular vesicles (EVs) and outer membrane vesicles (OMVs), and shed cell-envelope fragments and lipids. We synthesize evidence spanning barrier biology, immunometabolic regulation, infection and inflammatory injury, cancer immunology, and microbiota-gut-brain axis research. Across models, effectors modulate the mucus and epithelial barrier to limit translocation and dampen Toll-like receptor (TLR) signaling, but mucus-active enzymes or antigenic epitopes may also create liabilities in susceptible hosts. Defined effectors can reproduce key whole-cell effects: in high-fat diet (HFD)/carbon tetrachloride (CCl4) liver injury, vesicle preparations matched or exceeded pasteurized bacteria; Amuc_1100 maps to immune reprogramming and barrier signaling; and P9 links microbial cues to glucagon-like peptide 1 (GLP-1) release. Key gaps include physiological dose realism, equivalence across colony-forming units (CFU) and protein or vesicle doses, strain and culture-condition dependence of effector expression, and limited human data for brain-relevant endpoints. Effector-defined preparations and engineered delivery systems may improve standardization and safety, but translation will require rigorous characterization, dose-response validation, and mechanism-linked biomarkers.